Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease

The ALZpath difference

ALZpath provides diagnostic tools and expertise in Alzheimer’s disease.  We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.

Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification

A timely and accessible diagnosis

Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:

  • Simple
  • Accessible
  • Timely
  • Cost-effective
  • Less invasive

pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.

Recent ALZpath News

Beckman Coulter Diagnostics to use ALZpath proprietary pTau antibody in Alzheimer’s diagnostic test

July 15, 2024

ALZpath announces a licensing agreement with Beckman Coulter Diagnostics to integrate its proprietary pTau217 antibody into a blood-based diagnostic for Alzheimer’s disease on Beckman Coulter’s DxI 9000 Immunoassay Analyzer. This in vitro diagnostic (IVD) test will enhance early and accurate Alzheimer’s diagnosis.

New Study in Alzheimer's & Dementia Reports Longitudinal pTau217

July 10, 2024

“Higher p-tau217 levels correlate with accelerated cognitive decline, thereby reinforcing the utility of p-tau217 as a powerful predictor of preclinical AD progression” as demonstrated in a critical new study by Dr. Du and team in the Wisconsin Registry for Alzheimer’s Prevention. This important research provides insights into longitudinal changes in plasma pTau217 and the capacity for this biomarker to predict cognitive decline.

Chad Holland Announced as ALZpath President and CEO

July 9, 2024

ALZpath announces the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company co-founder and former CEO, chose to step aside to take on an advisory role. Holland brings a deep skillset in commercialization, business development, and fundraising, perfectly positioning him to accelerate the company’s growth.

ALZpath Partners with Roche to Provide pTau217 Antibody for Alzheimer's Diagnostic Blood Test

June 10, 2024

ALZpath has announced a strategic license agreement with Roche for use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer’s disease diagnostic blood test that will be offered by Roche. The Roche pTau217 test was recently granted Breakthrough Device designation by the FDA and will be commercialized as part of an ongoing collaboration between Roche and Eli Lilly.